Assessment of satisfaction, compliance with medical recommendations and quality of life on the basis on the observational, non-interventional, multi-center study to evaluate the efficacy of the therapeutic process with Daivobet® gel in the treatment of psoriasis as a part of routine medical practice

Introduction
The use of topical combination preparations, in case of which it is possible to reduce the frequency of daily applications, can improve the patients’ satisfaction with topical therapy.

Objective
The present study analyzes the results of treatment with Daivobet® gel, with a particular emphasis on patient satisfaction with treatment, impact on quality of life and compliance with physicians' recommendations by patients with psoriasis.

Material and methods
Total 401 patients with plaque psoriasis (mild in 38.7%, moderate in 52.6% and severe in 8.5% of patients) were included into the study. It was an observational, non-interventional, multicenter study using Daivobet® gel in routine medical practice. The severity of psoriasis was assessed using the PGA tool (Physician Global Assessment), and the quality of life was scored using the DLQI scale (Dermatology Life Quality Index). At visit 2, overall treatment satisfaction, response to treatment, as well as treatment tolerance and compliance were assessed.

Results
At visit 2, the majority of patients were satisfied or very satisfied with the treatment (65.5% and 22.0%, respectively). At the second and third visit, approximately one-third of the patients were almost completely free from symptoms (30.3% at visit 2 and 38.6% at visit 3) (p < 0.001). The mean value of DLQI at the start of the study was 11.5 ±6.3 points and was significantly reduced at visit 2 (mean: 5.3 ±4.2 points) and further decreased at visit 3 (mean 3.1 ±3.4 points) (p < 0.001).

Conclusions
Obtained results proved to be consistent with the current knowledge about high efficacy, improvement of quality of life and good tolerability of treatment in patients using the combination preparation containing calcipotriol and betamethasone dipropionate.